COMMUNIQUÉS West-GlobeNewswire

KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies

12/09/2024 - 10:21

RIYADH, Saudi Arabia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionising infectious disease diagnostics with advanced Whole Genome Sequencing (WGS) and [...]

The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024

12/09/2024 - 10:21

The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever presentation of the [...]

Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024

12/09/2024 - 10:21

Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter pour la première [...]

Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme

12/09/2024 - 10:00

Grant to advance development of Cryptigen immunotherapeutics for cancer CAMBRIDGE, United Kingdom and MONTREAL, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing [...]

Epitopea reçoit une subvention dans le cadre du programme Cancer Therapeutics d’Innovate UK

12/09/2024 - 10:00

Subvention pour la mise au point de produits d’immunothérapie visant les TSA Cryptigen dans le traitement du cancer CAMBRIDGE, Royaume-Uni et MONTRÉAL, 12 sept. 2024 (GLOBE NEWSWIRE) -- Epitopea, société transatlantique [...]

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

12/09/2024 - 07:00

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative [...]

Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares

12/09/2024 - 07:00

Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares Paris (France) et Houston (Texas), le 12 septembre [...]

Genespire appoints Karen Aiach-Pignet as Chief Executive Officer

12/09/2024 - 07:00

PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12 September 2024 – Genespire [...]

Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares

12/09/2024 - 07:00

Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares Paris (France) et Houston (Texas), le 12 septembre [...]

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

12/09/2024 - 07:00

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing varoglutamstat, a Phase 2 [...]

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

12/09/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers [...]

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

11/09/2024 - 23:37

– U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults COPENHAGEN, Denmark, Sept. 11, 2024 (GLOBE NEWSWIRE) -- [...]

Streamline Health® Reports Fiscal Second Quarter 2024 Financial Results

11/09/2024 - 22:30

Net loss of ($2.8 million) during the second quarter of fiscal 2024 compared to a net loss of ($2.5 million) during the second quarter of fiscal 2023 Adjusted EBITDA improved to a loss of ($0.3 million) for the second [...]

Teva to Present at the Bank of America 2024 Global Healthcare Conference

11/09/2024 - 22:30

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 [...]

iSpecimen Announces 1-for-20 Reverse Stock Split

11/09/2024 - 22:30

WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]

Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit

11/09/2024 - 22:30

SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]

Annual Report 2023/24 - Strengthened commercial focus after challenging year

11/09/2024 - 22:29

ANNOUNCEMENT NO. 273 11 September 2024 Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec’s revenue fell by 8% in 2023/24 to DKK 407.4 million, and [...]

Guidance for the 2024/25 financial year

11/09/2024 - 22:27

ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial year ChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information. For [...]

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

11/09/2024 - 22:05

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]